Retoxin® Receives Regulatory Approval in China for Aesthetic Use

Chongqing Claruvis Pharmaceutical Co., Ltd. announced that the National Medical Products Administration (NMPA) of China approved its Retoxin® (recombinant botulinum toxin type A, project code YY001) for the temporary amelioration of moderate-to-severe glabellar lines in adult patients.

Transitioning from Natural Extraction Techniques to Precision Genetic Engineering

Claruvis Pharmaceutical has developed Retoxin® using its proprietary recombinant platform and manufacturing system. This product preserves the molecular structure of the active protein (the core 150 kDa neurotoxin structure) while mitigating the biosafety risks associated with traditional Clostridium botulinum-derived production methods and delivering a toxin characterized by high purity and specific activity.

Retoxin® stands as the worlds first approved recombinant botulinum toxin type A, representing a significant technological advancement over conventional botulinum toxin products derived from Clostridium botulinum.

Retoxin® signifies the inaugural commercial achievement from our recombinant platform, validating our vision of advancing next-generation botulinum neurotoxins that offer improved purity, consistency, and safety, stated Dr. Yang, Chief Scientific Officer of Claruvis Pharmaceutical. The company is committed to establishing a robust pipeline of recombinant products tailored to address a wide array of neurological and aesthetic indications.

As per precedence research, the global botulinum toxin market was valued at approximately USD 9.48 billion, with projections indicating an increase from USD 10.39 billion in 2026 to an estimated USD 23.34 billion by 2035, reflecting a CAGR of 9.43% from 2026 to 2035, with an anticipated growth rate of 12.0% by 2030. This market expansion is driven by rising disposable incomes, an increasing acceptance of minimally invasive cosmetic procedures, and expanding therapeutic indications.

Industry Impact and Market Outlook

Claruvis Pharmaceutical has pioneered the first recombinant botulinum toxin type A to achieve regulatory approval, marking a transition from traditional extraction techniques to precision recombinant manufacturing. The organization remains dedicated to delivering safer and higher-quality therapeutic and aesthetic solutions on a global scale.

Additionally, Claruvis is advancing Retoxin® for the treatment of adult upper limb spasticity resulting from stroke or traumatic brain injury, having successfully conducted a Phase II clinical trial in China and currently enrolling participants in a multi-center Phase III program across over 20 clinical sites in the country. These developments not only introduce new revenue avenues but also attract investments in research and development, solidifying the role of botulinum toxin as a versatile solution for diverse medical requirements.